CommercialCoverageMedium impact
08.01.22e, Alemtuzumab (Lemtrada®)
Independence Blue Cross·Neurology, Oncology, Hematology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
IBX Commercial has updated their policy 08.01.22e for Alemtuzumab (Lemtrada®), a specialty pharmacy medication. This is a fresh policy update that took effect October 1, 2025, but specific details about coverage, prior authorization, or billing changes are not provided in the summary.
Action Required
By October 1, 2025: Billing team should review the full policy details at the provided URL to understand specific changes to Alemtuzumab (Lemtrada®) coverage requirements. Update prior authorization workflows and billing procedures as needed based on the complete policy document. Contact IBX directly if clarification is needed on coverage criteria.